3BBLACKBIO3B Blackbio Dx Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on 3BBLACKBIO — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 50.6% YoY
- • ROE: 18.5%
- • Debt/Equity: 0.01
- • Volume: 1.7x 20-day average
- • 3-month vs NIFTY: +12.0% relative
- • 6-month vs NIFTY: +11.2% relative
Bull case
- • Revenue growth: 50.6% YoY
- • ROE: 18.5%
- • Debt/Equity: 0.01
- • Volume: 1.7x 20-day average
Bear case
- • Profit growth: -29.0% YoY
- • Dividend yield: 0.35%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Profit growth: -29.0% YoY
- • Dividend yield: 0.35%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹99.12). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.